JAVEMACS: JAVELIN Bladder 100 Subset Review - Real-World Effectiveness of First-Line Avelumab in Japanese Patients

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Hiroshi Kitamura, MD, of the University of Toyama, discussed the design and outcomes of the real-world JAVEMACS study which analyzed Japanese patients with locally advanced or metastatic urothelial carcinoma who received first-line avelumab maintenance therapy.

Dr. Kitamura shares the differences observed between the JAVEMACS and JAVELIN Bladder 100 patient cohorts, and how JAVEMACS helps to add to the existing data on avelumab for this patient population.